Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Cantor Fitzgerald upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, up from $100, as the analyst took over ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic ...

Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

In Hulu’s The Handmaid’s Tale, every outfit isn’t just about style it’s about power, suppression, and survival. Each piece of ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

Whether you loved it or hated it, there was no questioning the show’s impact. “The Handmaid’s Tale” hauled in eight Emmy ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...